Protagonist Therapeutics Turns Takeda Payments Into $274.4 Million Revenue Quarter And A Profit

MIMRYLO approval payments drove the earnings reversal as Protagonist funds its own drug candidates and plans share repurchases.

Share
Protagonist Therapeutics Turns Takeda Payments Into $274.4 Million Revenue Quarter And A Profit

Protagonist Therapeutics, which develops peptide medicines for immune diseases, blood disorders and obesity, reported third-quarter license and collaboration revenue of $274.4 million, versus $4.7 million a year earlier, in results released Thursday with an SEC filing. Payments triggered by FDA approval of its Takeda-partnered medicine MIMRYLO dominated the quarter, which produced a $220.0 million profit against a year-earlier $39.3 million loss.

Approval Payments Drive The Reversal

Protagonist booked $266.6 million of revenue tied to $275.0 million earned from Takeda during the quarter. The cash arrived in October: a $200.0 million opt-out payment and a $75.0 million approval milestone. Development services under the Takeda agreement and other revenue supplied the remaining $7.8 million.

Diluted earnings reached $3.07 per share, compared with a $0.62 loss a year earlier. For the first nine months, revenue totaled $544.3 million versus $38.6 million, while net income reached $386.6 million, or $5.43 per diluted share, against a loss of $85.8 million, or $1.35 per share.

The nine-month revenue included $460.5 million recognized from Takeda payments, $33.8 million from development services under that partnership and a $50.0 million Johnson & Johnson milestone earned upon ICOTYDE’s FDA approval in the first quarter, plus other revenue.

Cash, cash equivalents and marketable securities stood at $834.6 million on September 30, compared with $646.0 million at the end of 2025. That quarter-end balance preceded the October Takeda receipts.

Royalties Remain After Takeda Takes Over

MIMRYLO, or rusfertide, treats excess red blood cells in adults with polycythemia vera, a rare blood disorder. Its U.S. approval was announced on August 28; approval in the United Arab Emirates followed on September 30. Protagonist discovered the drug and led its clinical development through the FDA approval application in December 2025.

Protagonist opted out of joint development and commercialization in April 2026, leaving Takeda with exclusive worldwide rights. Protagonist remains eligible for royalties of 14% to 29% of worldwide net sales and up to $875 million in additional milestones. The agreement’s weighted-average royalty rate would be approximately 21% at $1.5 billion in annual net sales.

Its other approved medicine, ICOTYDE, is an oral psoriasis treatment licensed to Janssen Biotech, a Johnson & Johnson company. Launched in the U.S. in March 2026, it gained approvals in China, Japan and the European Union during the third quarter—its second full quarter of U.S. sales.

ICOTYDE royalties range from 6% to 10%, with an approximate 7.25% weighted-average rate at $4 billion in annual global net sales and a 10% rate on incremental sales above that level. Protagonist is eligible for up to $580 million in further milestones. ICOTYDE is also in late-stage development for psoriatic arthritis, ulcerative colitis and Crohn’s disease.

The board authorized up to $300 million in share repurchases on September 8. Protagonist intends to use cash, securities and partnership receipts; purchase timing and amounts depend on market conditions, other uses of capital and other factors.

Dinesh V. Patel, Protagonist’s president and CEO, said the partnerships provide flexibility “to fund the next generation of wholly owned programs emerging from our platform,” and “to return meaningful capital to shareholders through a share repurchase program,” in the earnings release.

Owned Drugs Bring Higher Research Spending

Research and development expense reached $41.274 million, compared with $40.003 million a year earlier. Protagonist expects spending to rise for the remainder of 2026 as it advances clinical programs, invests in manufacturing readiness and discovery work, and adds personnel and stock-based pay. Lower spending on rusfertide’s late-stage trial partly offset increases in its own programs.

PN-881, its oral immune-disease candidate, completed an early-stage study and was generally well tolerated, with no serious adverse events. Once-daily dosing maintained drug concentrations above the company’s targeted levels over 24 hours. Protagonist plans a mid-stage dose-ranging psoriasis trial early in the first quarter of 2027.

Encouraging dose-related findings from an early-stage study of injectable obesity candidate PN-477sc led Protagonist to prioritize its oral version, PN-477o. The company anticipates an early-stage trial in the first half of 2027.

Preparatory studies are also underway for oral obesity candidate PN-458o and oral blood-disorder candidate PN-8047. Protagonist anticipates early-stage trials in the second half of 2027 and the first quarter of 2027, respectively, while continuing discovery work on oral IL-4 receptor blockers and amylin-based candidates.

The next planned clinical step is PN-881’s psoriasis trial early in the first quarter of 2027, putting partnership-funded development of a wholly owned medicine at the center of Protagonist’s next phase.

Sources